Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (51929)	2/1/2022 3:46:17 PM
From: Art Bechhoefer	Read Replies (1) \| Respond to of 52153

"Surely the important comparisons are effectiveness, safety, and side-effects?" Absolutely! And even though 100 mg doesn't seem very large, the higher the dosage, the more likely to have safety or other problems. Remember as well that there can be interactions BETWEEN different drugs, which is especially applicable to us older people who take a lot of different medications. And finally, which I didn't mention in the last post, the FDA lost a lot of credibility when it approved the BIIB drug that had shown little efficacy for many Alzheimer's patients. Denial of approval on drugs submitted later on was, it appears, partly a reaction to the FDA overruling its advisory committee and the subsequent resignations of many of those committee members. One can't be sure how the FDA will react either to the Madrigal or the Viking drugs. Just one more area of uncertainty. Art